Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 2.43 Million USD | 224.82% |
| 2021 | 749.43 Thousand USD | -43.92% |
| 2020 | 1.33 Million USD | 25.03% |
| 2019 | 1.06 Million USD | 238.17% |
| 2018 | 316.07 Thousand USD | -86.57% |
| 2017 | 2.35 Million USD | -96.18% |
| 2016 | 61.59 Million USD | 0.85% |
| 2015 | 61.07 Million USD | 80.05% |
| 2014 | 33.92 Million USD | 22.6% |
| 2013 | 27.66 Million USD | 185.63% |
| 2012 | 9.68 Million USD | 49.91% |
| 2011 | 6.46 Million USD | 10253.88% |
| 2010 | 62.41 Thousand USD | -99.43% |
| 2009 | 10.94 Million USD | 80.01% |
| 2008 | 6.08 Million USD | 11.66% |
| 2007 | 5.44 Million USD | -19.05% |
| 2006 | 6.72 Million USD | 8.06% |
| 2005 | 6.22 Million USD | 7.73% |
| 2004 | 5.77 Million USD | 748.75% |
| 2003 | 680.81 Thousand USD | 253.87% |
| 2002 | 192.39 Thousand USD | -1.23% |
| 2001 | 194.79 Thousand USD | 30.19% |
| 2000 | 149.61 Thousand USD | -96.7% |
| 1999 | 4.53 Million USD | 202.9% |
| 1998 | 1.49 Million USD | -38.31% |
| 1997 | 2.42 Million USD | 95.76% |
| 1996 | 1.24 Million USD | -17.33% |
| 1995 | 1.5 Million USD | -6.25% |
| 1994 | 1.6 Million USD | 433.33% |
| 1993 | 300 Thousand USD | 200.0% |
| 1992 | 100 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | 1.25 Million USD | -5.89% |
| 2023 Q1 | 2.31 Million USD | -4.77% |
| 2023 Q2 | 1.33 Million USD | -42.25% |
| 2022 Q3 | 1.82 Million USD | 116.47% |
| 2022 Q2 | 840.77 Thousand USD | 159.97% |
| 2022 Q1 | 323.41 Thousand USD | -56.85% |
| 2022 FY | 2.43 Million USD | 224.82% |
| 2022 Q4 | 2.43 Million USD | 33.75% |
| 2021 Q1 | 704.25 Thousand USD | -47.3% |
| 2021 Q2 | 434.32 Thousand USD | -38.33% |
| 2021 Q3 | 380.52 Thousand USD | -12.39% |
| 2021 Q4 | 749.43 Thousand USD | 96.95% |
| 2021 FY | 749.43 Thousand USD | -43.92% |
| 2020 Q1 | 957.64 Thousand USD | -10.4% |
| 2020 Q3 | 1.03 Million USD | -8.0% |
| 2020 FY | 1.33 Million USD | 25.03% |
| 2020 Q4 | 1.33 Million USD | 29.48% |
| 2020 Q2 | 1.12 Million USD | 17.16% |
| 2019 Q3 | 824.67 Thousand USD | -12.71% |
| 2019 Q1 | 1.12 Million USD | 256.49% |
| 2019 Q2 | 944.72 Thousand USD | -16.16% |
| 2019 FY | 1.06 Million USD | 238.17% |
| 2019 Q4 | 1.06 Million USD | 29.61% |
| 2018 Q4 | 316.07 Thousand USD | -88.58% |
| 2018 FY | 316.07 Thousand USD | -86.57% |
| 2018 Q1 | 2.96 Million USD | 25.78% |
| 2018 Q2 | 2.81 Million USD | -4.75% |
| 2018 Q3 | 2.76 Million USD | -1.81% |
| 2017 Q2 | 1.99 Million USD | -5.01% |
| 2017 Q1 | 2.1 Million USD | -96.59% |
| 2017 Q4 | 2.35 Million USD | 18.77% |
| 2017 Q3 | 1.98 Million USD | -0.8% |
| 2017 FY | 2.35 Million USD | -96.18% |
| 2016 Q2 | 61.17 Million USD | 0.53% |
| 2016 Q1 | 60.85 Million USD | -0.37% |
| 2016 Q4 | 61.59 Million USD | -0.97% |
| 2016 Q3 | 62.2 Million USD | 1.68% |
| 2016 FY | 61.59 Million USD | 0.85% |
| 2015 Q4 | 61.07 Million USD | -0.33% |
| 2015 Q1 | 35.39 Million USD | 4.35% |
| 2015 FY | 61.07 Million USD | 80.05% |
| 2015 Q2 | 59.16 Million USD | 67.15% |
| 2015 Q3 | 61.28 Million USD | 3.57% |
| 2014 Q1 | 30.93 Million USD | 11.82% |
| 2014 FY | 33.92 Million USD | 22.6% |
| 2014 Q2 | 31.22 Million USD | 0.91% |
| 2014 Q4 | 33.92 Million USD | 4.44% |
| 2014 Q3 | 32.48 Million USD | 4.04% |
| 2013 Q2 | 27.3 Million USD | 109.89% |
| 2013 Q3 | 27.77 Million USD | 1.73% |
| 2013 FY | 27.66 Million USD | 185.63% |
| 2013 Q4 | 27.66 Million USD | -0.4% |
| 2013 Q1 | 13 Million USD | 34.3% |
| 2012 Q3 | 6.01 Million USD | -8.43% |
| 2012 Q1 | 6.51 Million USD | 0.75% |
| 2012 Q4 | 9.68 Million USD | 60.92% |
| 2012 FY | 9.68 Million USD | 49.91% |
| 2012 Q2 | 6.57 Million USD | 0.97% |
| 2011 Q2 | 9072.00 USD | -74.78% |
| 2011 Q4 | 6.46 Million USD | 0.0% |
| 2011 FY | 6.46 Million USD | 10253.88% |
| 2011 Q1 | 35.97 Thousand USD | -42.36% |
| 2011 Q3 | - USD | -100.0% |
| 2010 Q1 | 10.95 Million USD | -0.23% |
| 2010 FY | 62.41 Thousand USD | -99.43% |
| 2010 Q4 | 62.41 Thousand USD | 177.44% |
| 2010 Q3 | 22.49 Thousand USD | -11.3% |
| 2010 Q2 | 25.36 Thousand USD | -99.77% |
| 2009 FY | 10.94 Million USD | 80.01% |
| 2009 Q1 | 6.12 Million USD | 0.7% |
| 2009 Q4 | 10.97 Million USD | 0.22% |
| 2009 Q3 | 10.95 Million USD | 75.96% |
| 2009 Q2 | 6.22 Million USD | 1.66% |
| 2008 Q1 | 5.49 Million USD | 0.87% |
| 2008 Q4 | 6.08 Million USD | 5.1% |
| 2008 Q2 | 5.65 Million USD | 2.96% |
| 2008 FY | 6.08 Million USD | 11.66% |
| 2008 Q3 | 5.78 Million USD | 2.3% |
| 2007 Q4 | 5.44 Million USD | -11.46% |
| 2007 FY | 5.44 Million USD | -19.05% |
| 2007 Q1 | 6.29 Million USD | -6.46% |
| 2007 Q2 | 6.09 Million USD | -3.19% |
| 2007 Q3 | 6.15 Million USD | 0.97% |
| 2006 Q2 | 6.36 Million USD | 1.15% |
| 2006 Q1 | 6.28 Million USD | 1.02% |
| 2006 FY | 6.72 Million USD | 8.06% |
| 2006 Q4 | 6.72 Million USD | 4.46% |
| 2006 Q3 | 6.44 Million USD | 1.24% |
| 2005 Q2 | 5.86 Million USD | 0.61% |
| 2005 Q4 | 6.22 Million USD | 5.25% |
| 2005 FY | 6.22 Million USD | 7.73% |
| 2005 Q1 | 5.82 Million USD | 0.89% |
| 2005 Q3 | 5.91 Million USD | 0.84% |
| 2004 Q3 | 195.88 Thousand USD | -1.53% |
| 2004 FY | 5.77 Million USD | 748.75% |
| 2004 Q1 | 249.1 Thousand USD | -63.41% |
| 2004 Q2 | 198.92 Thousand USD | -20.14% |
| 2004 Q4 | 5.77 Million USD | 2849.93% |
| 2003 FY | 680.81 Thousand USD | 253.87% |
| 2003 Q4 | 680.81 Thousand USD | 57.52% |
| 2003 Q3 | 432.2 Thousand USD | -0.62% |
| 2003 Q2 | 434.89 Thousand USD | 297.08% |
| 2003 Q1 | 109.52 Thousand USD | -43.07% |
| 2002 Q4 | 192.39 Thousand USD | -90.49% |
| 2002 Q1 | 125.17 Thousand USD | -35.74% |
| 2002 Q2 | 1.05 Million USD | 742.52% |
| 2002 Q3 | 2.02 Million USD | 91.86% |
| 2002 FY | 192.39 Thousand USD | -1.23% |
| 2001 Q4 | 194.79 Thousand USD | 442.55% |
| 2001 Q1 | 102.34 Thousand USD | -31.6% |
| 2001 FY | 194.79 Thousand USD | 30.19% |
| 2001 Q2 | 54.12 Thousand USD | -47.12% |
| 2001 Q3 | 35.9 Thousand USD | -33.67% |
| 2000 Q3 | 46.9 Thousand USD | -83.06% |
| 2000 Q1 | 319.53 Thousand USD | -41.9% |
| 2000 FY | 149.61 Thousand USD | -96.7% |
| 2000 Q4 | 149.61 Thousand USD | 218.99% |
| 2000 Q2 | 276.81 Thousand USD | -13.37% |
| 1999 Q1 | 1.4 Million USD | -6.51% |
| 1999 Q3 | 560 Thousand USD | -56.92% |
| 1999 Q4 | 550 Thousand USD | -1.79% |
| 1999 FY | 4.53 Million USD | 202.9% |
| 1999 Q2 | 1.3 Million USD | -7.14% |
| 1998 Q2 | 5.2 Million USD | 10.64% |
| 1998 FY | 1.49 Million USD | -38.31% |
| 1998 Q4 | 1.49 Million USD | -71.74% |
| 1998 Q1 | 4.7 Million USD | 93.61% |
| 1998 Q3 | 5.3 Million USD | 1.92% |
| 1997 Q2 | 2 Million USD | 42.86% |
| 1997 Q3 | 2.1 Million USD | 5.0% |
| 1997 Q4 | 2.42 Million USD | 15.6% |
| 1997 Q1 | 1.4 Million USD | 12.9% |
| 1997 FY | 2.42 Million USD | 95.76% |
| 1996 Q4 | 1.24 Million USD | -27.06% |
| 1996 Q1 | 900 Thousand USD | -40.0% |
| 1996 Q2 | 800 Thousand USD | -11.11% |
| 1996 Q3 | 1.7 Million USD | 112.5% |
| 1996 FY | 1.24 Million USD | -17.33% |
| 1995 Q2 | 500 Thousand USD | 0.0% |
| 1995 Q4 | 1.5 Million USD | 0.0% |
| 1995 Q1 | 500 Thousand USD | -68.75% |
| 1995 FY | 1.5 Million USD | -6.25% |
| 1995 Q3 | 1.5 Million USD | 200.0% |
| 1994 FY | 1.6 Million USD | 433.33% |
| 1994 Q3 | 600 Thousand USD | 0.0% |
| 1994 Q4 | 1.6 Million USD | 166.67% |
| 1994 Q2 | 600 Thousand USD | 50.0% |
| 1994 Q1 | 400 Thousand USD | 33.33% |
| 1993 Q4 | 300 Thousand USD | 200.0% |
| 1993 FY | 300 Thousand USD | 200.0% |
| 1993 Q1 | - USD | -100.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1992 FY | 100 Thousand USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q4 | 100 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -391.779% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -788.432% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 97.978% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | -15.206% |
| Azitra, Inc. | 885.94 Thousand USD | -174.769% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -5985.912% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | -91.876% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | 66.358% |
| CEL-SCI Corporation | 13.57 Million USD | 82.063% |
| iBio, Inc. | 4.46 Million USD | 45.419% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | 17.537% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 31.544% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | 11.157% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -678.472% |
| BiomX Inc. | 15.09 Million USD | 83.87% |
| BiomX Inc. | 15.09 Million USD | 83.87% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 90.737% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | -312.358% |
| Scorpius Holdings, Inc. | 14.04 Million USD | 82.664% |